-
Signature
-
/s/ Mardi Dier, as Attorney-in-Fact
-
Issuer symbol
-
MDGL
-
Transactions as of
-
10 Dec 2025
-
Net transactions value
-
-$10,002,903
-
Form type
-
4
-
Filing time
-
12 Dec 2025, 16:35:12 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Taub Rebecca |
Director |
C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN |
/s/ Mardi Dier, as Attorney-in-Fact |
12 Dec 2025 |
0001423898 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
MDGL |
Common Stock |
Options Exercise |
$294,670 |
+18,650 |
+4% |
$15.80 |
479,694 |
10 Dec 2025 |
Direct |
|
| transaction |
MDGL |
Common Stock |
Sale |
$268,949 |
-491 |
-0.1% |
$547.76 |
479,203 |
10 Dec 2025 |
Direct |
F1, F2 |
| transaction |
MDGL |
Common Stock |
Sale |
$202,418 |
-369 |
-0.08% |
$548.56 |
478,834 |
10 Dec 2025 |
Direct |
F1, F3 |
| transaction |
MDGL |
Common Stock |
Sale |
$267,335 |
-486 |
-0.1% |
$550.07 |
478,348 |
10 Dec 2025 |
Direct |
F1, F4 |
| transaction |
MDGL |
Common Stock |
Sale |
$2,602,307 |
-4,723 |
-0.99% |
$550.99 |
473,625 |
10 Dec 2025 |
Direct |
F1, F5 |
| transaction |
MDGL |
Common Stock |
Sale |
$2,433,641 |
-4,410 |
-0.93% |
$551.85 |
469,215 |
10 Dec 2025 |
Direct |
F1, F6 |
| transaction |
MDGL |
Common Stock |
Sale |
$2,132,197 |
-3,857 |
-0.82% |
$552.81 |
465,358 |
10 Dec 2025 |
Direct |
F1, F7 |
| transaction |
MDGL |
Common Stock |
Sale |
$1,709,826 |
-3,087 |
-0.66% |
$553.88 |
462,271 |
10 Dec 2025 |
Direct |
F1, F8 |
| transaction |
MDGL |
Common Stock |
Sale |
$569,822 |
-1,027 |
-0.22% |
$554.84 |
461,244 |
10 Dec 2025 |
Direct |
F1, F9 |
| transaction |
MDGL |
Common Stock |
Sale |
$111,078 |
-200 |
-0.04% |
$555.39 |
461,044 |
10 Dec 2025 |
Direct |
F1 |
| transaction |
MDGL |
Common Stock |
Gift |
$0 |
-5,455 |
-1.2% |
$0.000000 |
455,589 |
10 Dec 2025 |
Direct |
F10 |
| holding |
MDGL |
Common Stock |
|
|
|
|
|
655,540 |
10 Dec 2025 |
By SQN LLC |
F11 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
MDGL |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-18,650 |
-50% |
$0.000000 |
18,650 |
10 Dec 2025 |
Common Stock |
18,650 |
$15.80 |
Direct |
F12 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: